In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Cardiometabolic Risk and Vascular Disease - from Mechanisms to Treatment

ESC Working Group on Peripheral Circulation

Peripheral Artery Disease
Aortic Disease, Peripheral Vascular Disease, Stroke

"Cardiometabolic Risk and Vascular Disease - from Mechanisms to Treatment"
The Official Working Group Symposium

3-5 November 2011 Rome, Italy

The symposium was designed to address the pathophysiology, diagnosis and treatment of cardiometabolic risk and discuss its impact in clinical practice.

This three-day programme offered a comprehensive update on the cardiometabolic risk presented by a distinguished international teaching Faculty.

Broad spectrums of important topics have been magistrally covered by the experts including arterial aging from its genetic and environmental determinants to assessment and putative management. Then, the role of classical and novel risk factors has been addressed giving particular evidence to the concept of dysglycemia, abdominal obesity and inflammatory pathways.

Several sessions were dedicated to address how we can improve evidence-based management of cardiometabolic risk focusing on new redox targets, utility of vascular imaging and biomarkers as well as the crucial issue related to the implementation of guideline targets. Furthermore, the putative strategies which go beyond glycemic control, with a window on peripheral arterial disease and nephroprotection, were also discussed.

One session was dealing with the two main actors on the battle field: lipids and diabetes, addressing the need for intense glucose and LDL-lowering as well as lipid management beyond LDL, focusing on the importance for individualized treatments.
Two special lectures were dedicated to the recent ESC Practice Guidelines on Diabetes & Cardiovascular Disease and Diagnosis & Treatment of Peripheral Arterial Diseases.

I am delighted to announce that the Proceedings of our Symposium on “Cardiometabolic risk and Vascular Diseases – from Mechanisms to Treatment” will be published in Current Vascular Pharmacology soon.

I do believe that our goal to promote an interactive learning environment under the umbrella of the Working Group on Peripheral Circulation has been achieved. Undoubtedly, it has also emerged from the very lively discussions the need for networking among cardiologists, angiologists, internists and diabetologists to implement a successful collaboration across specialty borders.

Prof. Francesco Cosentino
ESC Working Group on Peripheral Circulation